Johnson & Johnson’s Janssen has entered into an agreement potentially worth up to $1.6 billion to develop and market Argenx’ cusatuzumab for a number of cancers, including haematological malignancies.
News
NHS to offer new non-invasive procedure for patients with faulty heart valve
An innovative, non-invasive procedure to repair faulty valves in the heart has been approved by the National Institute for Health and Care Excellence for use on the NHS.
OPEN Health merges with Peloton Advantage
Health communications and market access group OPEN Health has merged with medical communications firm Peloton Advantage in a move designed to broaden the range of services available to clients.
Entries are surpassing last year – get yours in now!
Entries for this years’ PharmaTimes International Clinical Researcher of the Year competition are pouring in – with more entries than this time last year as we approach the busy Christmas period.
Roche’s Hemlibra shows sustained bleed control in children
Roche’s Hemlibra has shown sustained bleed control in a late-stage trial involving 85 children with haemophilia A.
Janssen unveils new data backing wider use of Darzalex
Janssen has unveiled data from a late-stage trial backing earlier use of its first-in-class biologic daratumumab (marketed as Darzalex) in patients with mutiple myeloma.
Shield’s Feraccru accepted for review in the US
Shield Therapeutics’ iron deficiency drug Feraccru has been accepted for review by the US Food and Drug Administration (FDA).
New cancer drugs taking longer to reach NHS patients
A new report by The Institute of Cancer Research (ICR) has found that NHS patients are waiting longer for new cancer drugs because of delays in taking them through clinical trials and getting them approved for use.
Novartis’ SMA therapy gets US priority review
US regulators have accepted for review Novartis’ Biologics License Application for Zolgensma, an investigational gene replacement therapy for the treatment of spinal muscular atrophy (SMA) Type 1.
New UK Health Data Research Alliance to boost medical research
The UK’s leading academics and health data specialists are being brought together under a new alliance that aims to develop new ways to design and support the medical research of the future, to ultimately improve the care patients receive from the NHS.
UK cancer patients waiting months for accurate diagnosis
Cancer patients in the UK have reported that they continue to face difficulties in receiving a timely diagnosis, according to a survey commissioned by the All.Can initiative, presented at the Britain Against Cancer conference in London.
NICE backs Cimzia for psoriasis, but rejects Ilumetri
Cost watchdog the National Institute for Health and Care Excellence has backed NHS funding for UCB’s Cimzia as a treatment for psoriasis, but is not recommending Almirall’s Ilumetri.
GSK adds to cancer offering with $5.1bn Tesaro buy
GlaxoSmithKline is buying US oncology biopharma Tesaro for $5.1 billion, marking the first major purchase by the firm since chief executive Emma Walmsley took charge last year.
Novartis’ Kymriah shows ‘strong efficacy’, ‘durable response’ in new analysis
Novartis has released longer-term analyses of data from the ELIANA and JULIET trials showing that its CAR-T cell therapy Kymriah demonstrated “strong efficacy” and “durable responses” in certain blood cancer patients.
UK to pursue deals and acquisitions despite Brexit uncertainty
The UK pharmaceutical industry is pressing ahead with M&A activity and is “geared to weather any disruption due to Brexit”, suggest results of a recent survey by EY.
